Zelira Therapeutics Meets Primary Endpoints for Phase (1b/2a) Medicinal Cannabis Trial for Insomnia
23 chronic insomnia patients treated with ZLT-101, Zelira’s proprietary and patented medicinal cannabis formulation, demonstrated statistically significant improvement in Insomnia Severity Index scores compared to placebo.
